Table 3: Demographic and clinical characteristics of RA patients and comparisons between subgroups.

Variables

Low baPWV group ()

High baPWV group ()

P

Age (years), mean ± SD

0.008

Female, n (%)

60 (78.95)

51 (82.26)

0.626

Weight (kg), mean ± SD

0.325

Height (cm), mean ± SD

0.033

BMI (kg/m^{2}), mean ± SD

0.389

SBP (mmHg), mean ± SD

0.084

DBP (mmHg), mean ± SD

0.215

Cholesterol (mmol/L), mean ± SD

0.035

Triglycerides (mmol/L), mean ± SD

0.004

HDL (mmol/L), mean ± SD

0.538

LDL (mmol/L), mean ± SD

0.006

Glucose (mmol/L), mean ± SD

0.434

Disease duration (months), mean (IQR)

24 (8, 66)

48 (12, 132)

0.169

RF-IgG positive, n (%)

46 (60.53)

34 (54.84)

0.501

RF-IgA positive, n (%)

37 (48.68)

28 (45.16)

0.100

RF-IgM positive, n (%)

56 (73.68)

52 (83.87)

0.149

Anti-CCP positive, n (%)

55 (72.37)

43 (69.35)

0.698

ESR (mm/h), mean ± SD

0.172

CRP (mg/dL), mean (IQR)

13.90 (5.34, 28.55)

18.15 (6.24, 68.05)

0.447

DAS28, mean ± SD

0.113

Currently using DMARDs, n (%)

5 (6.58)

4 (6.45)

0.976

Currently using NSAIDs, n (%)

38 (50.00)

36 (58.06)

0.345

Data are given as mean ± SD when normally distributed, as median (25–75%) when nonnormally distributed, or as number (and percentage). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score for 28 joint indices; IQR: interquartile range; DMARDs: disease-modifying antirheumatic drugs; NSAIDs: nonsteroidal anti-inflammatory drugs.